Taken together, the biomarker kinetics suggest that despite minimal anti-tumor activity, vandetanib and cetuximab may adequately suppress target (EGFR and VEGFR2) activity in metastatic colorectal cancer. This evidence concerns the gene EGFR and metastatic colorectal cancer.